1[1]CrulM, KlerkdeGJ, Swart M, etal. Phase Ⅰclinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol, 2002, 20 (11) :2726 被引量：1
3[3]Alex A Adjei, Charles Erlichman, Jenny N Davis, et al. A phase Ⅰ trial of the farnesyl transferase inhibitor SCH66366:Evidence for biological and clinical activity. Cancer Res, 2000,60:1871 被引量：1
4[4]Roy S Herbst, Edward S Kim. Novel therapeutic options for non small cell lung cancer (second line and suhsequent therapy).American Society of Clinical Oncology Educational Book, 2003, 654 被引量：1
5[5]Lipton Allan, Ready N Bukowski RM, et al. Phase Ⅰ study of continuous oral lonafarnib plus weekly paclitaxel for advanced cancer. ASCO Annual Meeting Abstract 2002, 364 被引量：1
6[6]Zujewski J, Horak ID, Bol CJ, et al. Phase Ⅰ and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol, 2000, 18:927 被引量：1
7[7]Karp JE, Lancet JE, de Solms SJ, et al. Clinical and biologic activity of the farnesyl transferase inhibitor R115777 in adults with refractory and relapsed acute leukemia: A phase Ⅰ clinical laboratory correlative trial. Blood, 2001, 97:3361 被引量：1
8[8]Piccart Gebhart MJ, BranleF, de Valeriola D, et al. A phase Ⅰ clinical and pharmacokinetic trial of the farnesyl transferase inhibitor R115777 plus docetaxel: A promising combination in patients with solid tumors. ProcAmSocClinOncol, 2001, 20:80A, (Abstr 318) 被引量：1
9[10]van Cutsem E, van de Velde H, Kaasek P, et al. Phase Ⅲ trial of gemcitabine pluse tipiarnib compared with gemcitabine plus placebo in advanced pancreastic cancer. J Clin Oncol,2004, 22:1430 被引量：1
2Vogel C L,Cobleigh M A,Tripathy D,et al.Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer[J].J Clin Oncol,2002,20(3):719-726. 被引量：1
3CrulM,KlerkGJ,Swart M,et al.Phase Ⅰ clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer[J].J Clin Oncol,2002,20(11):2726-2735. 被引量：1
4Johnston S R,Kelland L R.Farnesyl transferase inhibitors-a novel therapy for breast cancer[J].Endocr Relat Cancer,2001,8(3):227-235. 被引量：1
5Chiu V K,Bivona T,Hach A,et al.Ras signaling on the endoplasmic reticulum and the Golgi[J].Nat Cell Biol,2002,4(5):343-350. 被引量：1
6Feldkamp M M,Lau N,Roncari L,et al.Isotype-specific Ras.GTP-levels predict the efficacy of farnesyltransferase inhibitors against human astrocytomas regardless of Ras mutational status[J].Cancer Res,2001,61 (10):4425-4431. 被引量：1
7Johnston S R,Hickish T,Ellis P,et al.Phase Ⅱ study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor,R115777,in advanced breast cancer[J].J Clin Oncol,2003,21 (13):2492-2499. 被引量：1
8Wherlock M,Gampel A,Futter C,et al.Farnesyltransferase inhibitors disrupt EGF receptor traffic through modulation of the RhoB GTPase[J].J Cell Sci,2004,117 (15):3221-3231. 被引量：1
9Chen Z,Sun J,Pradines A,et al.Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice[J].J Biol Chem,2000,275(24):17974-17978. 被引量：1
10Chun K H,Lee H Y,Hassan K,et al.Implication of protein kinase B/Akt and Bcl-2/Bcl-XL suppression by the farnesyl transferase inhibitor SCH66336 in apoptosis induction in squamous carcinoma cells[J].Cancer Res,2003,63(16):4796-4800. 被引量：1
